Recently Expired Drugs

1. Abilify Asimtufii patent expiration

ABILIFY ASIMTUFII's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8399469 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2025

(7 days ago)




Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 27 April, 2023

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

ABILIFY ASIMTUFII family patents

Family Patents

2. Abilify Maintena Kit patent expiration

ABILIFY MAINTENA KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8399469 OTSUKA PHARM CO LTD Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2025

(7 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Feb 28, 2016
M(M-150) Dec 05, 2017
New Indication(I-746) Jul 27, 2020

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 28 February, 2013

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE

How can I launch a generic of ABILIFY MAINTENA KIT before it's drug patent expiration?
More Information on Dosage

ABILIFY MAINTENA KIT family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Advair Hfa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7500444

(Pediatric)

GLAXO GRP LTD Actuation indicator for a dispensing device
Jul, 2025

(2 days ago)




Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 08 June, 2006

Treatment: NA

Dosage: AEROSOL, METERED

More Information on Dosage

ADVAIR HFA family patents

Family Patents

4. Alyftrek patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jun, 2025

(12 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 20, 2029

Drugs and Companies using DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM ingredient

NCE-1 date: 20 December, 2028

Market Authorisation Date: 20 December, 2024

Treatment: Treatment of a moderate to mild clinical phenotype of cf in patients aged 6 years and older who have at least one f508del mutation or another responsive mutation in the cftr gene with a pharmaceutical...

Dosage: TABLET

More Information on Dosage

ALYFTREK family patents

Family Patents

5. Amondys 45 patent expiration

AMONDYS 45's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9447415 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(8 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 25, 2026
Orphan Drug Exclusivity(ODE-347) Feb 25, 2028

Drugs and Companies using CASIMERSEN ingredient

NCE-1 date: 25 February, 2025

Market Authorisation Date: 25 February, 2021

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

AMONDYS 45 family patents

Family Patents

6. Arikayce Kit patent expiration

ARIKAYCE KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7718189 INSMED INC Sustained release of antiinfectives
Jun, 2025

(30 days ago)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-214) Sep 28, 2025
Generating Antibiotic Incentives Now(GAIN) Sep 28, 2030

Drugs and Companies using AMIKACIN SULFATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen

Dosage: SUSPENSION, LIPOSOMAL

More Information on Dosage

ARIKAYCE KIT family patents

Family Patents

7. Brixadi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8545832 BRAEBURN Lipid depot formulations
Jun, 2025

(30 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 23, 2026

Drugs and Companies using BUPRENORPHINE ingredient

Market Authorisation Date: 23 May, 2023

Treatment: A method of delivery of a bioactive agent by subcutaneous injection. a method of treatment of a human for addiction

Dosage: SOLUTION, EXTENDED RELEASE

More Information on Dosage

BRIXADI family patents

Family Patents

8. Bydureon patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(6 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 27, 2015
M(M-162) Sep 24, 2018
M(M-212) Oct 20, 2020
M(M-224) Apr 02, 2021
M(M-240) Feb 15, 2022
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea

Dosage: FOR SUSPENSION, EXTENDED RELEASE

More Information on Dosage

BYDUREON family patents

Family Patents

9. Bydureon Bcise patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(6 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 20, 2020
M(M-240) Feb 15, 2022
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

BYDUREON BCISE family patents

Family Patents

10. Bydureon Pen patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(6 days ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-224) Apr 02, 2021
M(M-240) Feb 15, 2022
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiab...

Dosage: FOR SUSPENSION, EXTENDED RELEASE

More Information on Dosage

BYDUREON PEN family patents

Family Patents

11. Dojolvi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186344 ULTRAGENYX PHARM INC Glycogen or polysaccharide storage disease treatment method
Jul, 2025

(5 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 30, 2025
Orphan Drug Exclusivity(ODE-311) Jun 30, 2027

Drugs and Companies using TRIHEPTANOIN ingredient

NCE-1 date: 30 June, 2024

Market Authorisation Date: 30 June, 2020

Treatment: NA

Dosage: LIQUID

More Information on Dosage

DOJOLVI family patents

Family Patents

12. Embeda patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685443 ALPHARMA PHARMS Sequestering subunit and related compositions and methods
Jul, 2025

(3 days ago)

US8685444 ALPHARMA PHARMS Sequestering subunit and related compositions and methods
Jul, 2025

(3 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Aug 13, 2012

Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 August, 2009

Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed

Dosage: CAPSULE, EXTENDED RELEASE

How can I launch a generic of EMBEDA before it's drug patent expiration?
More Information on Dosage

EMBEDA family patents

Family Patents

13. Exondys 51 patent expiration

EXONDYS 51's oppositions filed in EPO
EXONDYS 51 IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9018368 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(8 days ago)

US10781451 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(8 days ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8486907 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(8 days ago)

USRE47751 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(8 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 19, 2021
Orphan Drug Exclusivity(ODE) Sep 19, 2023
Orphan Drug Exclusivity(ODE-122) Sep 19, 2023

Drugs and Companies using ETEPLIRSEN ingredient

NCE-1 date: 19 September, 2020

Market Authorisation Date: 19 September, 2016

Treatment: (i)treatment of duchenne muscular dystrophy; (ii)restoring/increasing functional dystrophin protein; Or (iii) inducing skipping; Each of (i)-(iii) in patients having a confirmed mutation of the dmd ge...

Dosage: SOLUTION

More Information on Dosage

EXONDYS 51 family patents

Family Patents

14. Farxiga patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(6 days ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-157) Mar 11, 2018
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-212) Oct 20, 2020
M(M-238) Feb 22, 2022
New Indication(I-841) Oct 18, 2022
New Indication(I-834) May 05, 2023
New Indication(I-857) Apr 30, 2024
M(M-298) May 08, 2026
New Patient Population(NPP) Jun 12, 2027
Pediatric Exclusivity(PED) Dec 12, 2027

Drugs and Companies using DAPAGLIFLOZIN ingredient

NCE-1 date: 12 December, 2026

Market Authorisation Date: 08 January, 2014

Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide

Dosage: TABLET

How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage

FARXIGA family patents

Family Patents

15. Flovent Hfa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7500444

(Pediatric)

GLAXO GRP LTD Actuation indicator for a dispensing device
Jul, 2025

(2 days ago)




Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 14 May, 2004

Treatment: NA

Dosage: AEROSOL, METERED

How can I launch a generic of FLOVENT HFA before it's drug patent expiration?
More Information on Dosage

FLOVENT HFA family patents

Family Patents

16. Kaletra patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309613

(Pediatric)

ABBVIE Solid pharmaceutical dosage form
Jun, 2025

(12 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-124) Apr 27, 2013

Drugs and Companies using LOPINAVIR; RITONAVIR ingredient

Market Authorisation Date: 09 November, 2007

Treatment: NA

Dosage: TABLET

How can I launch a generic of KALETRA before it's drug patent expiration?
More Information on Dosage

KALETRA family patents

Family Patents

17. Kalydeco patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jun, 2025

(12 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 31, 2017
New Indication(I-740) Feb 21, 2017
New Indication(I-705) Dec 30, 2017
Orphan Drug Exclusivity(ODE) Jan 31, 2019
Orphan Drug Exclusivity(ODE-20) Jan 31, 2019
New Patient Population(NPP) May 03, 2026
Orphan Drug Exclusivity(ODE-186) Feb 21, 2021
Orphan Drug Exclusivity(ODE-187) Dec 29, 2021
Orphan Drug Exclusivity(ODE-188) Mar 17, 2022
Orphan Drug Exclusivity(ODE-190) May 17, 2024
Orphan Drug Exclusivity(ODE-189) Jul 31, 2024
Orphan Drug Exclusivity(ODE-199) Aug 15, 2025
Orphan Drug Exclusivity(ODE-236) Apr 29, 2026
Orphan Drug Exclusivity(ODE-338) Dec 21, 2027
Orphan Drug Exclusivity(ODE-435) May 03, 2030

Drugs and Companies using IVACAFTOR ingredient

NCE-1 date: 01 February, 2016

Market Authorisation Date: 03 May, 2023

Treatment: Treatment of a moderate to mild clinical phenotype of cf using ivacaftor in a patient age 4 months to <6 years who has one cftr mutation responsive to ivacaftor based on clinical and/or in vitro assay...

Dosage: GRANULE

How can I launch a generic of KALYDECO before it's drug patent expiration?
More Information on Dosage

KALYDECO family patents

Family Patents

18. Kalydeco patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS Modulators of ATP-binding cassette transporters
Jun, 2025

(12 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 31, 2017
New Indication(I-740) Feb 21, 2017
New Indication(I-705) Dec 30, 2017
Orphan Drug Exclusivity(ODE) Jan 31, 2019
Orphan Drug Exclusivity(ODE-20) Jan 31, 2019
New Patient Population(NPP) May 03, 2026
Orphan Drug Exclusivity(ODE-186) Feb 21, 2021
Orphan Drug Exclusivity(ODE-187) Dec 29, 2021
Orphan Drug Exclusivity(ODE-188) Mar 17, 2022
Orphan Drug Exclusivity(ODE-190) May 17, 2024
Orphan Drug Exclusivity(ODE-189) Jul 31, 2024
Orphan Drug Exclusivity(ODE-199) Aug 15, 2025
Orphan Drug Exclusivity(ODE-236) Apr 29, 2026
Orphan Drug Exclusivity(ODE-338) Dec 21, 2027
Orphan Drug Exclusivity(ODE-435) May 03, 2030

Drugs and Companies using IVACAFTOR ingredient

NCE-1 date: 01 February, 2016

Market Authorisation Date: 20 May, 2019

Treatment: Use of ivacaftor for treating cystic fibrosis in a patient with a mild to moderate cf phenotype with at least one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in ...

Dosage: TABLET

How can I launch a generic of KALYDECO before it's drug patent expiration?
More Information on Dosage

KALYDECO family patents

Family Patents

19. Kazano patent expiration

Can you believe KAZANO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2025

(12 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Jan 25, 2016
New Chemical Entity Exclusivity(NCE) Jan 25, 2018
M(M-177) Apr 05, 2019
M(M-300) Jul 27, 2026

Drugs and Companies using ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 25 January, 2017

Market Authorisation Date: 25 January, 2013

Treatment: NA

Dosage: TABLET

How can I launch a generic of KAZANO before it's drug patent expiration?
More Information on Dosage

KAZANO family patents

Family Patents

20. Latuda patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE45573 SUNOVION PHARMS INC Process for producing imide compound
Jun, 2025

(13 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-134) Apr 26, 2015
New Chemical Entity Exclusivity(NCE) Oct 28, 2015
New Indication(I-674) Jun 28, 2016
M(M-195) Jan 27, 2020
Pediatric Exclusivity(PED) Jul 27, 2020
New Patient Population(NPP) Mar 05, 2021

Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient

NCE-1 date: 28 July, 2019

Market Authorisation Date: 07 December, 2011

Treatment: NA

Dosage: TABLET

How can I launch a generic of LATUDA before it's drug patent expiration?
More Information on Dosage

LATUDA family patents

Family Patents

21. Mekinist patent expiration

Can you believe MEKINIST received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443 NOVARTIS Pyrimidine compound and medical use thereof
Jun, 2025

(26 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-678) Jan 08, 2017
New Chemical Entity Exclusivity(NCE) May 29, 2018
M(M-170) Nov 20, 2018
Orphan Drug Exclusivity(ODE) May 29, 2020
Orphan Drug Exclusivity(ODE-48) May 29, 2020
New Indication(I-745) Jun 22, 2020
Orphan Drug Exclusivity(ODE-57) Jan 08, 2021
New Indication(I-778) Apr 30, 2021
New Indication(I-781) May 04, 2021
M(M-246) Oct 06, 2022
Orphan Drug Exclusivity(ODE-148) Jun 22, 2024
Orphan Drug Exclusivity(ODE-182) Apr 30, 2025
Orphan Drug Exclusivity(ODE-183) May 04, 2025
New Indication(I-895) Jun 22, 2025
Pediatric Exclusivity(PED) Sep 16, 2026
New Indication(I-908) Mar 16, 2026
New Product(NP) Mar 16, 2026
Orphan Drug Exclusivity(ODE-428) Mar 16, 2030

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

Market Authorisation Date: 16 March, 2023

Treatment: In combination with dabrafenib for the treatment of unresectable or metastatic melanoma.

Dosage: SOLUTION; TABLET

More Information on Dosage

MEKINIST family patents

Family Patents

22. Nucynta patent expiration

NUCYNTA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7994364 COLLEGIUM PHARM INC Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Jun, 2025

(9 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 20, 2013
New Patient Population(NPP) Jul 03, 2026
Pediatric Exclusivity(PED) Jan 03, 2027

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

NCE-1 date: 03 January, 2026

Market Authorisation Date: 15 October, 2012

Treatment: Relief of moderate to severe acute pain

Dosage: SOLUTION; TABLET

How can I launch a generic of NUCYNTA before it's drug patent expiration?
More Information on Dosage

NUCYNTA family patents

Family Patents

23. Nucynta Er patent expiration

NUCYNTA ER IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7994364 COLLEGIUM PHARM INC Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Jun, 2025

(9 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 20, 2013
New Dosage Form(NDF) Aug 25, 2014
New Indication(I-656) Aug 28, 2015

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

NCE-1 date: 20 November, 2012

Market Authorisation Date: 25 August, 2011

Treatment: Relief of moderate to severe chronic pain

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of NUCYNTA ER before it's drug patent expiration?
More Information on Dosage

NUCYNTA ER family patents

Family Patents

24. Pomalyst patent expiration

POMALYST's oppositions filed in EPO
Can you believe POMALYST received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8198262 BRISTOL Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Jun, 2025

(19 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 08, 2018
New Indication(I-707) Apr 23, 2018
Orphan Drug Exclusivity(ODE) Feb 08, 2020
Orphan Drug Exclusivity(ODE-43) Feb 08, 2020
M(M-14) Nov 20, 2023
Orphan Drug Exclusivity(ODE-296) May 14, 2027
Orphan Drug Exclusivity(ODE-297) May 14, 2027
Pediatric Exclusivity(PED) Nov 14, 2027

Drugs and Companies using POMALIDOMIDE ingredient

NCE-1 date: 14 November, 2026

Market Authorisation Date: 08 February, 2013

Treatment: Use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on o...

Dosage: CAPSULE

How can I launch a generic of POMALYST before it's drug patent expiration?
More Information on Dosage

POMALYST family patents

Family Patents

25. Ryanodex patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7758890 EAGLE PHARMS Treatment using dantrolene
Jun, 2025

(6 days ago)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Jul 22, 2021
Orphan Drug Exclusivity(ODE-69) Jul 22, 2021

Drugs and Companies using DANTROLENE SODIUM ingredient

Market Authorisation Date: 22 July, 2014

Treatment: NA

Dosage: FOR SUSPENSION

More Information on Dosage

RYANODEX family patents

Family Patents

26. Solodyn patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268804 BAUSCH Minocycline oral dosage forms for the treatment of acne
Jun, 2025

(12 days ago)

US8252776 BAUSCH Minocycline oral dosage forms for the treatment of acne
Jun, 2025

(12 days ago)

US8722650 BAUSCH Extended-release minocycline dosage forms
Jun, 2025

(12 days ago)

US7790705 BAUSCH Minocycline oral dosage forms for the treatment of acne
Jun, 2025

(12 days ago)




Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 08 May, 2006

Treatment: Treatment of acne

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of SOLODYN before it's drug patent expiration?
More Information on Dosage

SOLODYN family patents

Family Patents

27. Symdeko (copackaged) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jun, 2025

(12 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 21, 2022
New Chemical Entity Exclusivity(NCE) Feb 12, 2023
Orphan Drug Exclusivity(ODE-173) Feb 12, 2025
Orphan Drug Exclusivity(ODE-247) Jun 21, 2026
Orphan Drug Exclusivity(ODE-335) Dec 21, 2027

Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient

NCE-1 date: 12 February, 2022

Market Authorisation Date: 21 June, 2019

Treatment: Tezacaftor and ivacaftor for the treatment of patients with a mild to moderate clinical phenotype of cystic fibrosis having at least one cftr gene mutation that is responsive to tezacaftor/ivacaftor b...

Dosage: TABLET

More Information on Dosage

SYMDEKO (COPACKAGED) family patents

Family Patents

28. Tafinlar patent expiration

Can you believe TAFINLAR received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443 NOVARTIS Pyrimidine compound and medical use thereof
Jun, 2025

(26 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-678) Jan 08, 2017
New Chemical Entity Exclusivity(NCE) May 29, 2018
M(M-170) Nov 20, 2018
Orphan Drug Exclusivity(ODE) May 29, 2020
Orphan Drug Exclusivity(ODE-47) May 29, 2020
New Indication(I-745) Jun 22, 2020
Orphan Drug Exclusivity(ODE-58) Jan 09, 2021
New Indication(I-778) Apr 30, 2021
New Indication(I-781) May 04, 2021
M(M-246) Oct 06, 2022
Orphan Drug Exclusivity(ODE-147) Jun 22, 2024
Orphan Drug Exclusivity(ODE-182) Apr 30, 2025
Orphan Drug Exclusivity(ODE-183) May 04, 2025
New Indication(I-894) Jun 22, 2025
Pediatric Exclusivity(PED) Sep 16, 2026
New Indication(I-908) Mar 16, 2026
New Product(NP) Mar 16, 2026
Orphan Drug Exclusivity(ODE-428) Mar 16, 2030

Drugs and Companies using DABRAFENIB MESYLATE ingredient

NCE-1 date: 22 December, 2024

Market Authorisation Date: 29 May, 2013

Treatment: Tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of ...

Dosage: CAPSULE; TABLET, FOR SUSPENSION

More Information on Dosage

TAFINLAR family patents

Family Patents

29. Tobi Podhaler patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8664187 VIATRIS Methods of treatment of endobronchial infections
Jun, 2025

(16 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 22, 2016

Drugs and Companies using TOBRAMYCIN ingredient

Market Authorisation Date: 22 March, 2013

Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa

Dosage: POWDER

More Information on Dosage

TOBI PODHALER family patents

Family Patents

30. Trikafta (copackaged) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jun, 2025

(12 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 08, 2024
New Chemical Entity Exclusivity(NCE) Oct 21, 2024
New Product(NP) Apr 26, 2026
Orphan Drug Exclusivity(ODE-275) Oct 21, 2026
M(M-313) Dec 20, 2027
ODE*(ODE*) Dec 21, 2027
Orphan Drug Exclusivity(ODE-323) Dec 21, 2027
Orphan Drug Exclusivity(ODE-357) Jun 08, 2028
Orphan Drug Exclusivity(ODE-433) Apr 26, 2030
Orphan Drug Exclusivity(ODE-512) Dec 20, 2031

Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient

NCE-1 date: 22 October, 2023

Market Authorisation Date: 08 June, 2021

Treatment: Treatment of a moderate to mild clinical phenotype of cf in patients aged 2 to <6 years who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based ...

Dosage: TABLET; GRANULES

More Information on Dosage

TRIKAFTA (COPACKAGED) family patents

Family Patents

31. Troxyca Er patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685443 PFIZER Sequestering subunit and related compositions and methods
Jul, 2025

(3 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Aug 19, 2019

Drugs and Companies using NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 August, 2016

Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed

Dosage: CAPSULE, EXTENDED RELEASE

More Information on Dosage

TROXYCA ER family patents

Family Patents

32. Ventolin Hfa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7500444

(Pediatric)

GLAXOSMITHKLINE Actuation indicator for a dispensing device
Jul, 2025

(2 days ago)




Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 19 April, 2001

Treatment: NA

Dosage: AEROSOL, METERED

More Information on Dosage

VENTOLIN HFA family patents

Family Patents

33. Vyleesi (autoinjector) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6794489 COSETTE Compositions and methods for treatment of sexual dysfunction
Jun, 2025

(8 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 21, 2024

Drugs and Companies using BREMELANOTIDE ACETATE ingredient

NCE-1 date: 22 June, 2023

Market Authorisation Date: 21 June, 2019

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

VYLEESI (AUTOINJECTOR) family patents

Family Patents

34. Vyondys 53 patent expiration

VYONDYS 53's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10227590 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(8 days ago)

US10968450 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(8 days ago)

US9024007 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(8 days ago)

US10421966 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(8 days ago)

US9994851 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(8 days ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10266827 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(8 days ago)

US10995337 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(8 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 12, 2024
Orphan Drug Exclusivity(ODE-280) Dec 12, 2026

Drugs and Companies using GOLODIRSEN ingredient

NCE-1 date: 13 December, 2023

Market Authorisation Date: 12 December, 2019

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients having a confirmed mutation of the dmd gene that is amenable to exon 53 skipping

Dosage: SOLUTION

More Information on Dosage

VYONDYS 53 family patents

Family Patents

35. Ximino patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7790705 JOURNEY Minocycline oral dosage forms for the treatment of acne
Jun, 2025

(12 days ago)

US8268804 JOURNEY Minocycline oral dosage forms for the treatment of acne
Jun, 2025

(12 days ago)

US8252776 JOURNEY Minocycline oral dosage forms for the treatment of acne
Jun, 2025

(12 days ago)




Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 11 July, 2012

Treatment: Treatment of acne

Dosage: CAPSULE, EXTENDED RELEASE

More Information on Dosage

XIMINO family patents

Family Patents

36. Xtampza Er patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8758813 COLLEGIUM PHARM INC Abuse-deterrent drug formulations
Jun, 2025

(26 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 26, 2019

Drugs and Companies using OXYCODONE ingredient

Market Authorisation Date: 26 April, 2016

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: CAPSULE, EXTENDED RELEASE

How can I launch a generic of XTAMPZA ER before it's drug patent expiration?
More Information on Dosage

XTAMPZA ER family patents

Family Patents